These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 17329552

  • 21. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
    Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C, Morari M.
    Peptides; 2010 Jun; 31(6):1194-204. PubMed ID: 20307605
    [Abstract] [Full Text] [Related]

  • 22. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
    Trapella C, Fischetti C, Pela' M, Lazzari I, Guerrini R, Calo' G, Rizzi A, Camarda V, Lambert DG, McDonald J, Regoli D, Salvadori S.
    Bioorg Med Chem; 2009 Jul 15; 17(14):5080-95. PubMed ID: 19527931
    [Abstract] [Full Text] [Related]

  • 23. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
    McDonald J, Calo G, Guerrini R, Lambert DG.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb 15; 367(2):183-7. PubMed ID: 12595960
    [Abstract] [Full Text] [Related]

  • 24. In vitro pharmacological profile of peptide III-BTD: a novel ligand for nociceptin/orphanin FQ and opioid receptors.
    Bigoni R, Rizzi A, Rizzi D, Becker JA, Kieffer BL, Simonin F, Regoli D, Calo G.
    Life Sci; 2000 Dec 01; 68(2):233-9. PubMed ID: 11191640
    [Abstract] [Full Text] [Related]

  • 25. Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors.
    Hashimoto Y, Calo' G, Guerrini R, Smith G, Lambert DG.
    Eur J Pharmacol; 2002 Aug 02; 449(1-2):17-22. PubMed ID: 12163101
    [Abstract] [Full Text] [Related]

  • 26. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.
    Neurobiol Dis; 2016 May 02; 89():55-64. PubMed ID: 26804029
    [Abstract] [Full Text] [Related]

  • 27. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.
    Molinari S, Camarda V, Rizzi A, Marzola G, Salvadori S, Marzola E, Molinari P, McDonald J, Ko MC, Lambert DG, Calo' G, Guerrini R.
    Br J Pharmacol; 2013 Jan 02; 168(1):151-62. PubMed ID: 22827708
    [Abstract] [Full Text] [Related]

  • 28. Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.
    McDonald J, Lambert DG.
    Br J Pharmacol; 2010 Mar 02; 159(6):1286-93. PubMed ID: 20148892
    [Abstract] [Full Text] [Related]

  • 29. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
    Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, Toll L.
    J Pharmacol Exp Ther; 2011 Nov 02; 339(2):687-93. PubMed ID: 21859931
    [Abstract] [Full Text] [Related]

  • 30. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
    Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ.
    J Pharmacol Exp Ther; 2008 Aug 02; 326(2):672-82. PubMed ID: 18492950
    [Abstract] [Full Text] [Related]

  • 31. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R, Caló G, Lambert DG, Carrá G, Arduin M, Barnes TA, McDonald J, Rizzi D, Trapella C, Marzola E, Rowbotham DJ, Regoli D, Salvadori S.
    J Med Chem; 2005 Mar 10; 48(5):1421-7. PubMed ID: 15743186
    [Abstract] [Full Text] [Related]

  • 32. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
    Dietis N, McDonald J, Molinari S, Calo G, Guerrini R, Rowbotham DJ, Lambert DG.
    Br J Anaesth; 2012 Feb 10; 108(2):262-70. PubMed ID: 22194444
    [Abstract] [Full Text] [Related]

  • 33. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.
    Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Iwasawa Y, Ohta H.
    Eur J Pharmacol; 2000 Jan 17; 387(3):R17-8. PubMed ID: 10650183
    [Abstract] [Full Text] [Related]

  • 34. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
    Berger H, Calo' G, Albrecht E, Guerrini R, Bienert M.
    J Pharmacol Exp Ther; 2000 Aug 17; 294(2):428-33. PubMed ID: 10900215
    [Abstract] [Full Text] [Related]

  • 35. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.
    Corboz MR, Rivelli MA, Egan RW, Tulshian D, Matasi J, Fawzi AB, Benbow L, Smith-Torhan A, Zhang H, Hey JA.
    Eur J Pharmacol; 2000 Aug 18; 402(1-2):171-9. PubMed ID: 10940371
    [Abstract] [Full Text] [Related]

  • 36. In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).
    Kitayama M, McDonald J, Barnes TA, Calo' G, Guerrini R, Rowbotham DJ, Lambert DG.
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug 18; 375(6):369-76. PubMed ID: 17598088
    [Abstract] [Full Text] [Related]

  • 37. Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.
    Calo' G, Guerrini R, Bigoni R, Rizzi A, Marzola G, Okawa H, Bianchi C, Lambert DG, Salvadori S, Regoli D.
    Br J Pharmacol; 2000 Mar 18; 129(6):1183-93. PubMed ID: 10725267
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13)NH(2), [(3)H]nociceptin/orphaninFQ(1-17)OH and [(125)I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors.
    Hashiba E, Lambert DG, Farkas J, Toth G, Smith G.
    Neurosci Lett; 2002 Aug 02; 328(1):5-8. PubMed ID: 12123846
    [Abstract] [Full Text] [Related]

  • 39. In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPgammaS in rat brain and spinal cord.
    Yamada S, Kusaka T, Urayama A, Kimura R, Watanabe Y.
    Br J Pharmacol; 2003 Aug 02; 139(8):1462-8. PubMed ID: 12922933
    [Abstract] [Full Text] [Related]

  • 40. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).
    Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Scheideler MA.
    J Pharmacol Exp Ther; 2004 Feb 02; 308(2):454-61. PubMed ID: 14593080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.